An application to conduct gene-editing research in human embryos, by the Francis Crick Institute in London, has been approved by the UK’s regulatory body, HFEA.… Read More »UK’s Human Fertilisation and Embryo Authority (HFEA) approves license for gene-editing in human embryos
Results from a Phase II study to evaluate the safety and efficacy of a micro- injectable formulation of triamcinolone for the treatment of macular edema… Read More »Phase II clinical trial results for micro-injection of triamcinolone in treatment of macular edema (following non-infectious uveitis) reaches primary endpoint
Results from a Phase III study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal insert (FAI, “Medidur”), for the treatment of… Read More »Phase III clinical trial results for corticosteroid flucinolone acetonide insert reports statistically significant results
Systematic research into the use of patient reported outcomes in clinical trials for AMD has concluded that adoption of an agreed standard tool would improve… Read More »Systematic research shows insufficient use of patient reported outcomes in AMD clinical trials.
Clinical results data announced at the 15th EURETINA Congress meeting reported that patients receiving “X-82”, a tyrosine kinase inhibitor under development by Tyrogenex Inc, Florida,… Read More »Open label dose-escalation US study of oral anti-VEGF medication shows VA improvement ahead of Phase II trial
Research into the development of therapies for Stargardt disease will receive a significant boost following announcement of the largest co-funding investment to date by the… Read More »Phase I/II trial planned for Stargardt disease through collaboration between Foundation Fighting Blindness and Vision Medicine
Research conducted at the Cantonal Hospital of Lucerne, Switzerland suggests that treatment of newly diagnosed AMD patients with either aflibercept or ranibizumab appear to provide… Read More »Analysis of clinical practice in treatment of newly diagnosed wet AMD patients suggests similar outcomes between aflibercept and ranibizumab.
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced the results of what the company claims to be the “first randomized,… Read More »Phase III data is announced from a randomised controlled cross-over gene therapy trial for LCA treatment
A review in the journal Expert Opinion on Biological Therapy (http://dx.doi.org/10.1517/14712598.2016.1093110) has highlighted the existence of almost 20 clinical trials, either completed or on-going, in… Read More »University of California review highlights increasing activity in clinical trial stem cell research
Clinical research performed by the Department of Ophthalmology, University of Bonn, Germany, has shown that microperimetry assessment in patients suffering macular telangiectasia type 2 (MacTel2)… Read More »Microperimetry may provide a more sensitive tool in measuring progression of macular telangiectasia type 2